The European Commission finally gives the first use of the drug against Alzheimer’s
Lecaneemab finally arrives at hospitals in Europe. At least in theory. Today, the nervous committee gave approval to use the hospital from … The first drug against Alzheimer’s disease, which allows 27 % slowing and for several months of progress. The approval of the doors open to various countries in the union, in turn, can weaken its use in its corresponding regional scope because the drug reaches patients once and forever.
The committee published a statement in which the authorization granted is limited to “the treatment of moderate perceptions in the early stages of pathology and under strict conditions.” The product, as remembered in the note, is intended for patients “with one copy or none of the APOE4 and Beta Amyloid genes in the brain”, which is in those who saw its benefit.
Initial doubts
The effectiveness of the product, at the present time, but this is always happening with all new drugs, as they remember professional organizations such as the Spanish Nerves Association (SEN). Initially, its use is often restricted in very specific cases, and since there is new scientific evidence, the utility extends, while the new generations of the drug improve its width, capabilities and form of dispensing, and it is usually simpler.
The approval submitted by the European Commission has finally reached five months after the Community Agency supported (EMA) recently, according to its original standards. Community health authorities spread after assessing the emergence of side effects in a specific group of patients and knowing that the experiments that allowed their approval in the United States, the United Kingdom, Japan, China, Israel and the Arab Emirates lasted only 18 months.
The bureaucracy continues
The drug, at the present time the injection is and is not effective for 15 % of the affected. All of these reasons led to EMA and the committee to enhance its conditional use, as happened in the United Kingdom, to the medicine prescribed by specialized doctors. Professional associations and the patient are eagerly awaiting the arrival of medicine, which they were demanding for more than a year. Countries, such as the United States, the United Kingdom, Japan and China, already provide a second drug, which allows treatment, although it is more specialized. The original concerns, however, ended up becoming a source of hope.
The ball is now on the roof of the public health systems of the various governments of the Federation, which must be the ones that finance medicine. The price they pay depends on the agreements, each of which reaches the manufacturer’s laboratory. In the case of Spain, the process, as always, will always be more complicated. The central government will direct negotiations with the pharmaceutical industry, but then the final decision will correspond to the regional health authorities, whose spending on its health budgets must be assumed.
